Skip to main content
Erschienen in: Clinical and Translational Medicine 1/2014

Open Access 01.12.2014 | Review

A review of research on salivary biomarkers for oral cancer detection

verfasst von: Yi-Shing Lisa Cheng, Terry Rees, John Wright

Erschienen in: Clinical and Translational Medicine | Ausgabe 1/2014

Abstract

Using saliva for disease diagnostics and health surveillance is a promising approach as collecting saliva is relatively easy and non-invasive. Over the past two decades, using salivary biomarkers specifically for early cancer detection has attracted much research interest, especially for cancers occurring in the oral cavity and oropharynx, for which the five-year survival rate (62%) is still one of the lowest among all major human cancers. More than 90% of oral cancers are oral squamous cell carcinoma (OSCC) and the standard method for detection is through a comprehensive clinical examination by oral healthcare professionals. Despite the fact that the oral cavity is easily accessible, most OSCCs are not diagnosed until an advanced stage, which is believed to be the major reason for the low survival rate, and points to the urgent need for clinical diagnostic aids for early detection of OSCC. Thus, much research effort has been dedicated to investigating potential salivary biomarkers for OSCC, and more than 100 such biomarkers have been reported in the literature. However, some important issues and challenges have emerged that require solutions and further research in order to find reliable OSCC salivary biomarkers for clinical use. This review article provides an up-to-date list of potential OSCC salivary biomarkers reported as of the fall of 2013, and discusses those emerging issues. By raising the awareness of these issues on the part of both researchers and clinicians, it is hoped that reliable, specific and sensitive salivary biomarkers may be found soon—and not only biomarkers for early OSCC detection but also for detecting other types of cancers or even for monitoring non-cancerous disease activity.
Hinweise

Competing interests

The authors declare that they have no commercial or other competing interests to disclose.

Authors’ contributions

The author YSLC reviewed and analyzed the published research studies, conceptualized and drafted the manuscript. TR and JW contributed important intellectual content for the manuscript. All three authors have been involved in revising the manuscript. All authors read and approved the final manuscript.
Abkürzungen
OSCC
Oral squamous cell carcinoma
OLP
Oral lichen planus
HPLC
High performance liquid chromatography
ELISA
Enzyme-linked immunosorbent assay
RIA
Radioimmunoassay
MALDI-TOF MS
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
2DE
Two-dimensional gel electrophoresis
qPCR
Quantitative polymerase chain reaction.

Introduction

Worldwide, cancers of the oral cavity and pharynx are the 6th most common type [1]. Although the incidence of oral and pharyngeal cancers is not considered high in the US (it accounts for approximately 3% of all malignancies in men and 2% of those in women) [1]-- its five-year survival rate has remained around 62%-- in contrast to the five-year survival rates for breast cancer (89%) and prostate cancer (99%) [2]. More than 90% of the oral cancers are squamous cell carcinomas (OSCC), which arise from the epithelial lining of the oral cavity. Even though the oral cavity is easily accessible for direct visual examination, most OSCCs are not diagnosed until an advanced stage, which is believed to be the major reason for the low survival rate. This underscores the importance of early and accurate detection by clinicians, as well as the need to educate the public about oral cancer risk factors and prevention.
In responding to the call for early detection of OSCC, several diagnostic adjuncts have been developed, or currently are in development, including the use of salivary biomarkers [35]. Saliva has been found to contain constituents that reflect the diseased or physiological state of the human body, and hence could be utilized for diagnostic purposes [68]. The search for reliable salivary biomarkers for early detection of OSCC has developed rapidly, spurred on by the fact that collecting saliva is relatively easy and non-invasive, compared to the drawing of blood. From the late 1990s until the present, more than 40 research studies have been published and more than 100 different salivary constituents have been suggested as potential OSCC salivary biomarkers (see Table 1). Several excellent reviews have been previously published concerning the basis for salivary diagnostics, and the history and evolution of salivary proteomic, transcriptomic, genomic, and metabolomic research for oral cancer detection [6, 7, 914]. This review article will provide an up-to-date list of potential OSCC salivary biomarkers, as of the fall of 2013, and will focus on some emerging issues/challenges that seem to be major roadblocks on the way to bringing reliable salivary biomarkers into actual clinical use. The intention of this review is to increase awareness of these issues on the part of both researchers and clinicians, with the hope that good solutions may be generated more quickly by group efforts in this field. Addressing these issues not only will serve to accelerate progress toward finding reliable salivary biomarkers for early OSCC detection, but also should have a positive effect on the search of reliable salivary biomarkers for other types of cancer detection or even for monitoring non-cancerous disease activity.
Table 1
Potential salivary biomarkers for oral cancer detection, reported as of 2013
Category
Potential OSCC salivary biomarkers
Authors/year
Non-organic compound
Na, Ca, F, and Mg
Shpitzer et al./2007 [55]
Peptide
Defensin-1
Mizukawa et al./1998 [28]
Proteins
P53 autoantibody
Warnakulasuriya et al./2000 [19]
α-amylase
Chen et al./2002 [20]
IL-8
St. John et al./2004 [23]
Rhodus et al./2005 [24]
Arellano-Garcia et al./2008 [70]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
TNF-α
Rhodus et al./2005 [24]
IL-1
IL-6
Rhodus et al./2005 [24]
Katakura et al./2007 [34]
Saheb-Jamee et al./2008 [35]
Sato et al./2010 [36]
Cheng et al./2013 [38]
Basic fibroblast growth factor
Vucicevic et al./2005 [27]
Gorugantula et al./2012 [39]
Statherin
Contucci et al./2005 [62]
Cyfra 21.1
Nagler et al./2006 [25]
Tissue polypeptide antigen (TPA)
Cancer antigen 125 (CA125)
Nagler et al./2006 [25]
Balan et al./2012 [57]
Endothelin-1
Pickering et al./2007 [21]
Cheng et al./2011 [40]
IL-1β
Katakura et al./2007 [34]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
CD44
Franzmann et al./2007 [46]
Total salivary protein
Shpitzer et al./2007 [55]
Insulin growth factor 1 (IGF-1)
MMP-2
MMP-9
Shpitzer et al./2007, 2009 [49, 55]
CD59
Hu et al./2008 [29]
Catalase
Profilin
S100A9/MRP14
M2BP
Hu et al./2008 [29]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
Carcinoembryonic antigen (CEA)
He et al./2009 [54]
Carcinoma associated antigen CA-50
Salivary carbonyls
Shipitzer et al./2009 [49]
Cyclin D1
Maspin
8-oxoguanine DNA glycosylase (OGG1)
Phosphorylated-Src
Ki-67
Lactate dehydrogenase
Shipitzer et al./2009 [49]
Shetty et al./2012 [58]
Transferrin
Jou et al./2010 [45]
Zinc finger protein 501 peptide
Jou et al./2011 [60]
Hemopexin
Jessie et al./2013 [59]
Haptoglobin
Complement C3
Transthyretin
α1-antitrypsin
DNAs
P53 gene codon 63
Liao et al./2000 [18]
Loss of heterozygosity in the combination of markers D3S1234, D9S156, and D17S799
El-Naggar et al./2001 [51]
Mitochondrial DNAs (cytochrome c oxidase I and cytochrome c oxidase II)
Jiang et al./2005 [37]
Hypermethylation of promoters in tumor suppressor genes: DAPK, DCC, MINT-31, TIMP-31, TIMP-3, p16, MGMT, CCNA1
Carvalho et al./2011 [61]
mRNAs
IL-8
Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
IL-1β
Li et al./2004 [22]
Elashoff et al./2012 [44]
DUSP1 (dual specificity phosphatase 1)
Li et al./2004 [22]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
H3F3A (H3 histone family 3A)
Li et al./2004 [22]
Elashoff et al./2012 [44]
OAZ1 (ornithin decarboxylase antizyme 1)
Li et al./2004 [22]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
S100P (S100 calcium binding protein P)
Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
Cheng et al./2013 [41]
SAT (spermidine/spermine N1-acetyltransferase EST)
Li et al./2004 [22]
Brinkmann et al./2011 [43]
Elashoff et al./2012 [44]
MicroRNAs
miR-125a
Park et al./2009 [31]
miR-200a
miR-31
Liu et al./2012 [33]
Long non-coding RNAs
HOTAIR
Tang et al./2013 [56]
Oxidative stress-related molecules
Reactive nitrogen species (RNS) such as nitric oxide (NO), nitrites (NO2) and nitrates (NO3)
Bahar et al./2007 [26]
Peroxidase
Bahar et al./2007 [26]
Glutathione S-transferase (GST)
Bahar et al./2007 [26]
Superoxide dismutase (SOD)
Agha-Hosseini et al./2012 [52]
8-hydroxy-2-deoxyguanosine (8-OHdG)
Glutathione
Almadori et al./2007 [30]
Malondialdehyde (MDA)
Agha-Hosseini et al./2012 [52]
Glucocorticoid
Cortisol
Bernabé et al./2012 [53]
Metabolomics
Cadaverine, alpha-aminobutyric acid, alanine, C5H14N5, piperidine, taurine piperideine, pipercolic acid, C4H9N, C8H9N, pyrroline hydroxycarboxylic acid, betaine, C6H6N2O2, leucine+isoleucine, tyrosine, histidine, tryptophan, beta-alanine, glutamic acid, threonine, serine, glutamine, choline, carnitine, C4H5N2O11P
Sugimoto et al./2010 [47]
Phenylalanine
Wei et al./2011 [48]
Sugimoto et al./2010 [47]
Valine
Wei et al./2011 [48]
Sugimoto et al./2010 [47]
Lactic acid
Wei et al./2011 [48]
Glycosylation- related molecules
Sialic acid
Vajaria et al./2013 [32]
α-L-fucosidase
Other
Telomerase activity
Zhong et al./2005 [50]

Review

Whole saliva (oral fluid) is unique and complex, both in its sources and composition. It consists not only of secretions from the three major salivary glands (parotid, submandibular and sublingual) and the minor glands, but also gingival crevicular fluid, oral mucosa transudate, secretions from nasal and pharyngeal mucosa, non-adherent bacteria, desquamated oral epithelial cells, keratin debris, blood cells, and perhaps food or medication residuals [8]. The functions of saliva include lubrication, digestion, antimicrobial activity, facilitating remineralization of the tooth enamel, and maintaining normal taste sensation [15]. These important functions are achieved by the various chemical components of saliva including water, inorganic compounds (ions), organic compounds (non-proteins and lipids), protein/polypeptides, and hormones [15]. Salivary proteins and polypeptides constitute a significant portion of the mix, and play an important role in carrying on the main functions of saliva. So far, more than 2300 proteins and peptides have been found in human saliva [16]. The most abundant proteins are α-amylase, albumin, cystatins, hystatins, secretory-IgA, lactoferrin, mucins, lysozymes, proline rich proteins, statherin and transferrin--which together account for more than 98% of the total salivary proteins [15, 17]. Most of the potential OSCC salivary biomarkers are also salivary proteins (see Table 1). However, except for three, α-amylase, statherin, and transferrin, those proteins, as well as the non-protein OSCC salivary biomarker candidates, are present in a very low concentration in saliva and require methods/instruments with high sensitivity for detection.

Reported potential salivary biomarkers for oral cancer detection

So far, more than 100 potential OSCC salivary biomarkers have been reported in the literature, based mainly on comparing the levels found in OSCC patients to the levels found in non-OSCC normal controls (see Table 1) [1862]. Some of these potential OSCC salivary biomarkers have been investigated by more than one research group; however, in some studies, no significant differences have been found in IL-6 [23], IL-8 [34, 35] and endothelin-1 [63] levels between the OSCC patients and their respective control groups.
The research methodology involved so far in investigating these potential OSCC salivary biomarkers can be grouped according to the types of biomarker, as follows:
1.
Non-organic compound biomarkers
Flame photometry, atomic absorption, and spectrophotometry [55]
 
2.
Peptide or protein biomarkers
High performance liquid chromatography (HPLC) [28, 62]
Enzyme-linked immunosorbent assay (ELISA) [19, 21, 23, 24, 27, 3436, 39, 40, 46, 49, 54, 55, 57]
Radio-immunoassay [25]
Two-dimensional gel electrophoresis (2DE), followed by mass spectrometry (MS) [59]
2DE and reverse-phase liquid chromatography (LC), followed by LC-tandem MS [29]
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) [20, 60]
2DE followed by MALDI-TOF MS [45]
 
3.
DNA, mRNA or microRNA biomarkers
Polymerase chain reaction (PCR) [18, 37, 51]
Quantitative PCR (qPCR) [31, 33, 4144, 56]
Microarrays followed by qPCR [22]
 
4.
Metabolomic biomarkers
Capillary electrophoresis TOF MS [47]
HPLC with quadrupole/TOF MS [48]
 
5.
Miscellaneous biomarkers (chemical and enzyme activity)
HPLC [30]
Colorimetric (mostly commercially available) assays [26, 32, 49, 50, 52, 53, 58]
 
Most OSCC salivary biomarker research has involved investigating the constituents of the whole saliva in an unstimulated state, although two studies did investigate the stimulated saliva samples [28, 36]. After a saliva sample is collected, a centrifugation processing procedure is often performed to remove the solid constituents (desquamated oral epithelial cells, keratin debris, blood cells, bacteria and food residuals, if any), but some studies appear to have analyzed the whole saliva content without centrifugation [46, 54, 58, 63, 64]. After separating out those solid constituents, samples were often stored in a frozen state until further analysis. Most salivary biomarker research studies have investigated only the supernatant (cell-free) portion of the saliva samples, while other studies investigated only the pellet portion of the saliva [50, 51, 61] or both the supernatant and the pellet portions [49] after centrifugation.

Issues/challenges in OSCC salivary biomarker research

1. A lack of standardization of conditions and methods of saliva sample collection, processing, and storage

Despite the fact that more than 100 potential OSCC salivary biomarkers have been reported, there has been no standardization regarding the condition of the subjects from whom the saliva samples are collected (e.g., the timing in regard to prior food and drink intake, or the use of oral hygiene products). Similarly, a uniform method has not been established for how the saliva samples are collected, processed and stored prior to measurement and comparison of the biomarker levels in the groups studied.
For example, in regard to participant requirements at the time of saliva collection, all researchers collected saliva samples in the morning, yet some researchers collected saliva samples from participants at least one hour after food intake [23, 25, 26, 63]; some collected saliva at least 1 1/2 hours after food intake [24]; and in ours and another study, we collected saliva in the morning before the participants ate, drank or performed any oral hygiene procedures [30, 3941]. In regard to saliva processing methods, most investigators centrifuged the saliva samples immediately after collection. However, they carried out this procedure with various degrees of centrifugal force and for various lengths of time, such as 800 g for 10 minutes [25, 26, 49]; 2000 g for 10 minutes [52]; 2600 g for 15 minutes [23, 32, 40, 41, 43]; 14,000 g for 20 minutes [59]; 2000 rpm (gravity not specified) for 5 minutes [53]; 3500 rpm (gravity not specified) for 15 minutes [34]; 14,000 rpm (gravity not specified) for 20 minutes [21]. Others stored the whole saliva samples at −80°C immediately after collection, then later thawed and centrifuged the samples at 4500 g for 20 minutes [35] or 6000 rpm (gravity not specified) for 20 minutes [24]. In regard to saliva sample preservation, we and some other investigators added proteinase inhibitors or RNase inhibitors to preserve salivary proteins and RNAs, respectively [22, 29, 3941], but most investigators did not add any inhibitors. In regard to saliva sample storage, most researchers stored the saliva samples in −80°C, although others stored samples at −20°C [28, 52, 54] or 4°C [30].
The differences in these factors among the different studies raises the question as to whether the levels of the potential OSCC salivary biomarkers reported in any one lab could be compared to the levels of the same biomarker reported in any other lab. In fact, for the reported potential biomarkers which have been investigated by more than one study, a wide variability was found in the levels of both the diseased and the control groups among different labs, and the different methods used for collecting and handling the saliva samples are likely to be one of the reasons for that variability. As research efforts will continue to be devoted to this promising field, standardization of saliva collection, processing and storage methods is essential, so that all the research findings among different research groups can be compared and validated, and progress accelerated toward finding the most reliable validated OSCC salivary biomarkers. Without such standardization and validation of biomarkers, valuable research resources are being squandered, because reported results cannot be translated into the desired clinical use and patient outcomes. A panel of experts in this research field is needed to discuss this issue and find a way to establish the standards needed.

2. Variability in the levels of potential OSCC salivary biomarkers in both non-cancerous individuals and OSCC patients, suggest unknown confounding factors

The wide variations noted in the reported levels of some of the salivary biomarker candidates among different research labs obviously creates difficulties in determining the reference level and the OSCC level for any given potential OSCC salivary biomarker. For example, salivary IL-6 and IL-8 are two of the most studied biomarkers, not only for potential OSCC detection but also for monitoring disease activity of chronic periodontitis and oral lichen planus (OLP)--a chronic mucocutaneous inflammatory disease that affects about 2% of the world population [65, 66]. As can be seen in Table 2[23, 24, 34, 35, 38, 6772], wide variations in the reported salivary IL-6 and IL-8 levels among the different studies were noted even in the healthy controls, with the average IL-6 levels ranging from 1.4 ± 0.9 pg/ml [24] to 47.46 ± 18.74 pg/ml [67], and IL-8 levels ranging from 250 pg/ml [23, 34, 35] to 1945 ± 181 pg/ml [68]. When the reference levels vary so much among the different studies, it is impossible to determine what ranges of salivary IL-6 or IL-8 levels are likely to indicate OSCC development. For example, the average salivary IL-8 levels found in OSCC patients in two studies were 720 pg/ml [23] and 1093.7 ± 1089.0 pg/ml [35], respectively --in contrast to 250 pg/ml and 700.7 ± 1031.5 pg/ml, respectively, in healthy controls. The average salivary IL-8 levels found in chronic periodontitis and healthy controls reported by Teles et al.[68] were 2268 ± 111 and 1945 ±181 pg/ml, respectively, both of which would most likely be considered in the concentration range for OSCC by the two previous studies reported by St John et al. [23] and SahebJamee et al. [35].
Table 2
Salivary Concentrations of IL-6 and IL-8 (pg/ml) in OSCC, OLP, and chronic periodontitis patient groups
Author/reographical region/year
OSCC
OLP
Chronic periodontitis
Controls
IL-6
IL-8
IL-6
IL-8
IL-6
IL-8
IL-6
IL-8
St. John et al./California, USA/2004[23]
 
720
   
250
Rhodus et al./Minnesota, USA/2005[24]
88.2± 43.2
3154.1±1023.2
  
1.4±0.9
1580± 789
Rhodus et al./Minnesota, USA/2005[67]
 
371.35±205.52
2194.3± 496.7
 
47.46±18.74
703.8± 131.6
Katakura et al./Tokyo, Japan/2007[34]
86.5
720
  
0
250
Zhang et al./Sichuan, China/2008[69]
 
48.79±8.53
1737.49±1073.54
 
29.9±4.68
641.46±172.91
Saheb Jamee et al./Tehran, Iran/2008[35]
40.9± 79.5
1093.7±1089.0
  
2.5±1.3
700.7± 1031.5
Arellano- Garcia et al./California, USA/2008[70]
 
3347.7±2929
   
759.4± 563
Teles et al./Massachusetts, USA/2009[68]
   
2268±111
 
1945±181
Sharma et al./Manipal, India/2011[71]
  
311.35±11.51
 
17.15±8.44
 
Ebersole et al./Kentucky, USA/2013[72]
  
35.57±48.17
 
3.30±2.32
 
Cheng et al./Texas, USA/2014[38]
178.41±172.32
1525.33±1123.95
20.74±22.28
1328.37±731.80
5.85±4.02
738.79±394.00
4.92±8.77
890.83±563.22
All studies investigated unstimulated whole saliva.
These wide variations in the levels of the same salivary constituent across the different research studies could be due at least partly to the different processing methods used, as described above. However, they may also possibly be due to inherent biological variations within different individuals and groups. In fact, some studies have reported intra- and inter-subject variability in salivary proteome and in specific potential OSCC salivary protein and mRNA biomarkers in studies of healthy adults [7375]. Inherent biological variations are known to create difficulties in determining the reference values for biological samples in clinical laboratories [76]. Such variations in salivary constituents could be attributed to differences in ethnic background, geographic locations, age, gender, non-neoplastic systemic diseases, dietary habits, medications being taken or other factors. For example, significantly increased levels in one of the potential salivary OSCC salivary biomarkers, endothein-1, have been reported in patients with chronic heart failure [77] or upper gastrointestinal diseases such as gastric ulcer, duodenal ulcer and gastritis [78] in the absence of OSCC. Age-related reduction in the concentrations of certain salivary proteins [79, 80] has also been reported, although whether there are any significant age-related changes in any of the reported potential OSCC salivary biomarkers has not been determined. In summary, the intra- and inter-subject variability points to an urgent need for more research regarding possibly underlying causes for these inherent biological variations, in order to refine and determine the appropriate reference range for any potential OSCC salivary biomarkers.

3. The need for further validation of OSCC salivary biomarkers

Validation in the presence of common oral inflammatory conditions
Ideally, a good clinical test requires high sensitivity and specificity. The oral cavity is commonly subject to inflammation from a variety of causes, including trauma, dental plaque, infection and certain mucocutaneous inflammatory diseases. Whether such oral inflammation (non-neoplastic conditions) affects the levels of the potential OSCC salivary biomarkers is essentially unknown, because most studies have investigated the potential salivary biomarker levels only in OSCC patients and non-OSCC controls, without regard for other inflammatory conditions that might have been present [9, 2127]. If the levels of any of the potential OSCC salivary biomarkers are increased in the presence of oral inflammation to a degree that there is no significant difference between those levels and the levels found in OSCC patients, it would result in a high false positive rate and greatly reduce the value of that biomarker in clinical use for OSCC detection.
In review of the reported potential OSCC salivary biomarkers, many of them-- such as IL-6[24, 34, 35], IL-8[23, 24, 70], IL-1β[22, 70], basic fibroblast growth factor[27], and molecules related to oxidative stress--[26, 30] are known to be important factors involved in inflammation and/or wound healing [81, 82]. Indeed, the levels of some of these salivary constituents have been reported to be significantly higher or lower in periodontitis or OLP patients who did not have OSCC [67, 69, 71, 72, 83, 84]. Therefore, research that validates any potential OSCC salivary biomarker with individuals having common non-neoplastic oral inflammatory diseases is necessary in order to establish the reliability of that salivary OSCC biomarker.
Validation in the presence of other types of human cancers
The advantages (being non-invasive and easy to collect) of using saliva over blood for disease detection and monitoring of disease progression encourage salivary biomarker research activities not only for OSCC detection but also for detection of other types of cancers. For instance, several potential salivary biomarkers for breast and lung cancer detection have been reported in recent years [8592]. Some of the reported salivary biomarkers for breast carcinomas, such as CA125 [91], haptoglobin, profilin-1 and transferrin [87]; and one reported salivary biomarker for lung cancer, S100 calcium binding protein A9 [86], are the same ones reported as potential OSCC salivary biomarkers [25, 29, 57, 59]. Salivary annexin A1, carbonic anhydrase VI, S100 calcium binding protein, and lipocalin have also been reported as potential biomarkers for both breast and lung cancers [86, 87]. These findings suggest that the levels of at least some salivary constituents could be significantly changed by the presence of more than one type of cancer, a fact which points to the necessity of validating the specificity of the reported potential OSCC salivary biomarkers with patients who have other types of cancers.

Conclusion

Salivary biomarkers represent a promising non-invasive approach for oral cancer detection, and an area of strong research interest. However, some issues/challenges have arisen that need to be resolved in order to establish this approach as a reliable, highly sensitive and specific method for clinical use. These issues include a lack of standardization for saliva sample collection, processing, and storage; wide variability in the levels of potential OSCC salivary biomarkers in both non-cancerous individuals and OSCC patients; and a need for further validation of OSCC salivary biomarkers with individuals who have either a chronic oral inflammatory disease or other types of cancers, but do not have OSCC. These issues call for convening a panel of researchers in this field to aim for eventual standardization, plus further research, especially concerning biological variance and physiological changes affecting the potential oral cancer salivary biomarkers. The experience gained in OSCC salivary biomarker research also can serve as an important reference in salivary diagnostics, including identifying, validating, and applying salivary biomarkers for other types of cancer detection and for monitoring non-cancerous disease activity.

Acknowledgements

Our research work regarding salivary biomarkers has been supported by the National Institute of Dental and Craniofacial Research (1R21DE018757: 5TL1RR024984; 5UL1RR024982), Texas A&M Health Science Center (TAMHSC), and Department of Diagnostic Sciences, Texas A&M University-Baylor College of Dentistry. We want to acknowledge Ms. Lee Jordan and Drs. Huey-Shys Chen, Emet Schneiderman, Jaqueline Plemons, Lance Oxford, David Kang, and John O’Brien, for their contributions to our previous and ongoing research regarding OSCC salivary biomarkers. We also want to thank Drs. David Carlson, Larry Wolinsky and Larry Bellinger for their strong support to our research work at Baylor College of Dentistry. Finally, Yi-Shing Lisa Cheng wishes to thank Dr. David Wong, Associate Dean of Research at UCLA, for his encouragement, invaluable advice and support over the years. His speech at the annual meeting of the American Academy of Oral and Maxillofacial Pathology in 2005 inspired our work in this field.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no commercial or other competing interests to disclose.

Authors’ contributions

The author YSLC reviewed and analyzed the published research studies, conceptualized and drafted the manuscript. TR and JW contributed important intellectual content for the manuscript. All three authors have been involved in revising the manuscript. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Chi AC: Squamous cell carcinoma. In Oral and Maxillofacial Pathology. Edited by: Neville BW, Damm DD, Allen CM, Bouquot JE. St. Louis: Saunders Elsevier; 2009:409–421. Chi AC: Squamous cell carcinoma. In Oral and Maxillofacial Pathology. Edited by: Neville BW, Damm DD, Allen CM, Bouquot JE. St. Louis: Saunders Elsevier; 2009:409–421.
2.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11–30. 10.3322/caac.21166CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11–30. 10.3322/caac.21166CrossRefPubMed
3.
Zurück zum Zitat Cheng Y, Wright J: Advances in diagnostic adjuncts for oral squamous cell carcinoma. The Open Pathology Journal 2011, 5: 3–7. 10.2174/1874375701105010003CrossRef Cheng Y, Wright J: Advances in diagnostic adjuncts for oral squamous cell carcinoma. The Open Pathology Journal 2011, 5: 3–7. 10.2174/1874375701105010003CrossRef
4.
Zurück zum Zitat Kalmar JR: Advances in the detection and diagnosis of oral precancerous and cancerous lesions. Oral Maxillofacial Surg Clin N Am 2006, 18: 465–82. 10.1016/j.coms.2006.06.013CrossRef Kalmar JR: Advances in the detection and diagnosis of oral precancerous and cancerous lesions. Oral Maxillofacial Surg Clin N Am 2006, 18: 465–82. 10.1016/j.coms.2006.06.013CrossRef
5.
Zurück zum Zitat Patton LL, Epstein JB, Kerr AR: Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc 2008, 139(7):896–905. 10.14219/jada.archive.2008.0276CrossRefPubMed Patton LL, Epstein JB, Kerr AR: Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc 2008, 139(7):896–905. 10.14219/jada.archive.2008.0276CrossRefPubMed
6.
Zurück zum Zitat Wong DT: Salivary diagnostics for oral cancer. J Calif Dent Assoc 2006, 34(4):303–8.PubMed Wong DT: Salivary diagnostics for oral cancer. J Calif Dent Assoc 2006, 34(4):303–8.PubMed
7.
Zurück zum Zitat Wong DT: Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 2006, 137(3):313–21. 10.14219/jada.archive.2006.0180CrossRefPubMed Wong DT: Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 2006, 137(3):313–21. 10.14219/jada.archive.2006.0180CrossRefPubMed
8.
Zurück zum Zitat Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, Calo L, Pisano E, Passali GC, Iavarone F, Paludetti G, Scarano E: Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital 2011, 31(6):347–57.PubMedCentralPubMed Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, Calo L, Pisano E, Passali GC, Iavarone F, Paludetti G, Scarano E: Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngol Ital 2011, 31(6):347–57.PubMedCentralPubMed
9.
Zurück zum Zitat Wu J, Yi C, Chung H, Wang D, Chang W, Lee S, Lin C, Yang Y, Yang W: Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncology 2010, 46: 226–31. 10.1016/j.oraloncology.2010.01.007CrossRefPubMed Wu J, Yi C, Chung H, Wang D, Chang W, Lee S, Lin C, Yang Y, Yang W: Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncology 2010, 46: 226–31. 10.1016/j.oraloncology.2010.01.007CrossRefPubMed
10.
11.
Zurück zum Zitat Nagler RM: Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol 2009, 45(12):1006–10. 10.1016/j.oraloncology.2009.07.005CrossRefPubMed Nagler RM: Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol 2009, 45(12):1006–10. 10.1016/j.oraloncology.2009.07.005CrossRefPubMed
12.
Zurück zum Zitat Brinkmann O, Wong DT: Salivary transcriptome biomarkers in oral squamous cell cancer detection. Adv Clin Chem 2011, 55: 21–34.CrossRefPubMed Brinkmann O, Wong DT: Salivary transcriptome biomarkers in oral squamous cell cancer detection. Adv Clin Chem 2011, 55: 21–34.CrossRefPubMed
14.
Zurück zum Zitat Zhang A, Sun H, Wang X: Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl Biochem Biotechnol 2012, 168(6):1718–27. 10.1007/s12010-012-9891-5CrossRefPubMed Zhang A, Sun H, Wang X: Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl Biochem Biotechnol 2012, 168(6):1718–27. 10.1007/s12010-012-9891-5CrossRefPubMed
15.
Zurück zum Zitat Chiappin S, Antonelli G, Gatti R, De Palo EF: Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta 2007, 383(1–2):30–40.CrossRefPubMed Chiappin S, Antonelli G, Gatti R, De Palo EF: Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta 2007, 383(1–2):30–40.CrossRefPubMed
16.
Zurück zum Zitat Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ: A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. J Proteome Res 2009, 8(12):5590–600. 10.1021/pr900675wPubMedCentralCrossRefPubMed Bandhakavi S, Stone MD, Onsongo G, Van Riper SK, Griffin TJ: A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva. J Proteome Res 2009, 8(12):5590–600. 10.1021/pr900675wPubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Messana I, Inzitari R, Fanali C, Cabras T, Castagnola M: Facts and artifacts in proteomics of body fluids. What proteomics of saliva is telling us? J Sep Sci 2008, 31(11):1948–63. 10.1002/jssc.200800100CrossRefPubMed Messana I, Inzitari R, Fanali C, Cabras T, Castagnola M: Facts and artifacts in proteomics of body fluids. What proteomics of saliva is telling us? J Sep Sci 2008, 31(11):1948–63. 10.1002/jssc.200800100CrossRefPubMed
18.
Zurück zum Zitat Liao PH, Chang YC, Huang MF, Tai KW, Chou MY: Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol 2000, 36(3):272–6. 10.1016/S1368-8375(00)00005-1CrossRefPubMed Liao PH, Chang YC, Huang MF, Tai KW, Chou MY: Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol 2000, 36(3):272–6. 10.1016/S1368-8375(00)00005-1CrossRefPubMed
19.
Zurück zum Zitat Warnakulasuriya S, Soussi T, Maher R, Johnson N, Tavassoli M: Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol 2000, 192(1):52–7. 10.1002/1096-9896(2000)9999:9999<::AID-PATH669>3.0.CO;2-CCrossRefPubMed Warnakulasuriya S, Soussi T, Maher R, Johnson N, Tavassoli M: Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol 2000, 192(1):52–7. 10.1002/1096-9896(2000)9999:9999<::AID-PATH669>3.0.CO;2-CCrossRefPubMed
20.
Zurück zum Zitat Chen YC, Li TY, Tsai MF: Analysis of the saliva from patients with oral cancer by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2002, 16(5):364–9. 10.1002/rcm.588CrossRefPubMed Chen YC, Li TY, Tsai MF: Analysis of the saliva from patients with oral cancer by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2002, 16(5):364–9. 10.1002/rcm.588CrossRefPubMed
21.
Zurück zum Zitat Pickering V, Jordan RC, Schmidt BL: Elevated salivary endothelin levels in oral cancer patients–a pilot study. Oral Oncol 2007, 43(1):37–41. 10.1016/j.oraloncology.2005.12.027CrossRefPubMed Pickering V, Jordan RC, Schmidt BL: Elevated salivary endothelin levels in oral cancer patients–a pilot study. Oral Oncol 2007, 43(1):37–41. 10.1016/j.oraloncology.2005.12.027CrossRefPubMed
22.
Zurück zum Zitat Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH, Wong DT: Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004, 10(24):8442–50. 10.1158/1078-0432.CCR-04-1167CrossRefPubMed Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH, Wong DT: Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004, 10(24):8442–50. 10.1158/1078-0432.CCR-04-1167CrossRefPubMed
23.
Zurück zum Zitat St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT: Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130(8):929–35. 10.1001/archotol.130.8.929CrossRefPubMed St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT: Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130(8):929–35. 10.1001/archotol.130.8.929CrossRefPubMed
24.
Zurück zum Zitat Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F: NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005, 29(1):42–5. 10.1016/j.cdp.2004.10.003CrossRefPubMed Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F: NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005, 29(1):42–5. 10.1016/j.cdp.2004.10.003CrossRefPubMed
25.
Zurück zum Zitat Nagler R, Bahar G, Shpitzer T, Feinmesser R: Concomitant analysis of salivary tumor markers–a new diagnostic tool for oral cancer. Clin Cancer Res 2006, 12(13):3979–84. 10.1158/1078-0432.CCR-05-2412CrossRefPubMed Nagler R, Bahar G, Shpitzer T, Feinmesser R: Concomitant analysis of salivary tumor markers–a new diagnostic tool for oral cancer. Clin Cancer Res 2006, 12(13):3979–84. 10.1158/1078-0432.CCR-05-2412CrossRefPubMed
26.
Zurück zum Zitat Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM: Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007, 109(1):54–9. 10.1002/cncr.22386CrossRefPubMed Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM: Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007, 109(1):54–9. 10.1002/cncr.22386CrossRefPubMed
27.
Zurück zum Zitat Vucicevic Boras V, Cikes N, Lukac J, Virag M, Cekic-Arambasin A: Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol 2005, 54(10):569–73.PubMed Vucicevic Boras V, Cikes N, Lukac J, Virag M, Cekic-Arambasin A: Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol 2005, 54(10):569–73.PubMed
28.
Zurück zum Zitat Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, Takagi S, Sugahara T: Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res 1998, 18(6B):4645–9.PubMed Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, Takagi S, Sugahara T: Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res 1998, 18(6B):4645–9.PubMed
29.
Zurück zum Zitat Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008, 14(19):6246–52. 10.1158/1078-0432.CCR-07-5037PubMedCentralCrossRefPubMed Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008, 14(19):6246–52. 10.1158/1078-0432.CCR-07-5037PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Almadori G, Bussu F, Galli J, Limongelli A, Persichilli S, Zappacosta B, Minucci A, Paludetti G, Giardina B: Salivary glutathione and uric acid levels in patients with head and neck squamous cell carcinoma. Head Neck 2007, 29(7):648–54. 10.1002/hed.20579CrossRefPubMed Almadori G, Bussu F, Galli J, Limongelli A, Persichilli S, Zappacosta B, Minucci A, Paludetti G, Giardina B: Salivary glutathione and uric acid levels in patients with head and neck squamous cell carcinoma. Head Neck 2007, 29(7):648–54. 10.1002/hed.20579CrossRefPubMed
31.
Zurück zum Zitat Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT: Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15(17):5473–7. 10.1158/1078-0432.CCR-09-0736PubMedCentralCrossRefPubMed Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT: Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15(17):5473–7. 10.1158/1078-0432.CCR-09-0736PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Vajaria BN, Patel KR, Begum R, Shah FD, Patel JB, Shukla SN, Patel PS: Evaluation of serum and salivary total sialic acid and alpha-l-fucosidase in patients with oral precancerous conditions and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 115(6):764–71. 10.1016/j.oooo.2013.01.004CrossRefPubMed Vajaria BN, Patel KR, Begum R, Shah FD, Patel JB, Shukla SN, Patel PS: Evaluation of serum and salivary total sialic acid and alpha-l-fucosidase in patients with oral precancerous conditions and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 115(6):764–71. 10.1016/j.oooo.2013.01.004CrossRefPubMed
33.
Zurück zum Zitat Liu C, Lin S, Yang C, Cheng H, Chang K: Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012, 34: 219–224. 10.1002/hed.21713CrossRefPubMed Liu C, Lin S, Yang C, Cheng H, Chang K: Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012, 34: 219–224. 10.1002/hed.21713CrossRefPubMed
34.
Zurück zum Zitat Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K, Takagi R, Shouno T: Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll 2007, 48(4):199–203. 10.2209/tdcpublication.48.199CrossRefPubMed Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K, Takagi R, Shouno T: Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll 2007, 48(4):199–203. 10.2209/tdcpublication.48.199CrossRefPubMed
35.
Zurück zum Zitat SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A: Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008, 13(5):E292–5.PubMed SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A: Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008, 13(5):E292–5.PubMed
36.
Zurück zum Zitat Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satob A, Kitagawa Y: Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2010, 110(3):330–336. 10.1016/j.tripleo.2010.03.040CrossRef Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satob A, Kitagawa Y: Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2010, 110(3):330–336. 10.1016/j.tripleo.2010.03.040CrossRef
37.
Zurück zum Zitat Jiang WW, Masayesva B, Zahurak M, Carvalho AL, Rosenbaum E, Mambo E, Zhou S, Minhas K, Benoit N, Westra WH, Alberg A, Sidransky D, Koch W, Califano J: Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res 2005, 11(7):2486–91. 10.1158/1078-0432.CCR-04-2147CrossRefPubMed Jiang WW, Masayesva B, Zahurak M, Carvalho AL, Rosenbaum E, Mambo E, Zhou S, Minhas K, Benoit N, Westra WH, Alberg A, Sidransky D, Koch W, Califano J: Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res 2005, 11(7):2486–91. 10.1158/1078-0432.CCR-04-2147CrossRefPubMed
38.
Zurück zum Zitat Cheng Y, Jordan L, Gorugantula L, Schneiderman E, Chen H, Rees T: Salivary interleukins 6 and 8 in oral cancer patients and in patients with chronic oral inflammatory diseases. J of Periodontology in press in press Cheng Y, Jordan L, Gorugantula L, Schneiderman E, Chen H, Rees T: Salivary interleukins 6 and 8 in oral cancer patients and in patients with chronic oral inflammatory diseases. J of Periodontology in press in press
39.
Zurück zum Zitat Gorugantula L, Rees T, Plemons J, Chen H, Cheng Y: Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol 2012, 114(2):215–22. 10.1016/j.oooo.2012.03.013PubMedCentralCrossRefPubMed Gorugantula L, Rees T, Plemons J, Chen H, Cheng Y: Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol 2012, 114(2):215–22. 10.1016/j.oooo.2012.03.013PubMedCentralCrossRefPubMed
40.
Zurück zum Zitat Cheng YS, Rees T, Jordan L, Oxford L, O'Brien J, Chen HS, Wong D: Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission. Oral Oncol 2011, 47(12):1122–6. 10.1016/j.oraloncology.2011.07.032PubMedCentralCrossRefPubMed Cheng YS, Rees T, Jordan L, Oxford L, O'Brien J, Chen HS, Wong D: Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission. Oral Oncol 2011, 47(12):1122–6. 10.1016/j.oraloncology.2011.07.032PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Cheng YS, Jordan L, Rees T, Chen HS, Oxford L, Brinkmann O, Wong D: Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients. Clin Oral Investig 2013. Jul 28 [Epub ahead of print] PMID: 23892499 Jul 28 [Epub ahead of print] PMID: 23892499 Cheng YS, Jordan L, Rees T, Chen HS, Oxford L, Brinkmann O, Wong D: Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients. Clin Oral Investig 2013. Jul 28 [Epub ahead of print] PMID: 23892499 Jul 28 [Epub ahead of print] PMID: 23892499
42.
Zurück zum Zitat Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA: Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008, 14(1):97–107. 10.1158/1078-0432.CCR-07-0722CrossRefPubMed Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA: Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008, 14(1):97–107. 10.1158/1078-0432.CCR-07-0722CrossRefPubMed
43.
Zurück zum Zitat Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, Nesic VS, Markovic SZ, Martinovic ZR, Akin D, Spielmann N, Zhou H, Wong DT: Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol 2011, 47(1):51–5. 10.1016/j.oraloncology.2010.10.009PubMedCentralCrossRefPubMed Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, Nesic VS, Markovic SZ, Martinovic ZR, Akin D, Spielmann N, Zhou H, Wong DT: Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol 2011, 47(1):51–5. 10.1016/j.oraloncology.2010.10.009PubMedCentralCrossRefPubMed
44.
Zurück zum Zitat Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abemayor E, Wong DT: Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 2012, 21(4):664–72. 10.1158/1055-9965.EPI-11-1093PubMedCentralCrossRefPubMed Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abemayor E, Wong DT: Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 2012, 21(4):664–72. 10.1158/1055-9965.EPI-11-1093PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, Tsai MH, Huang SH, Lin CW: Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta 2010, 681(1–2):41–8.CrossRefPubMed Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, Tsai MH, Huang SH, Lin CW: Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta 2010, 681(1–2):41–8.CrossRefPubMed
46.
Zurück zum Zitat Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ: Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(7):1348–55. 10.1158/1055-9965.EPI-06-0011CrossRefPubMed Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ: Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(7):1348–55. 10.1158/1055-9965.EPI-06-0011CrossRefPubMed
47.
Zurück zum Zitat Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6(1):78–95. 10.1007/s11306-009-0178-yPubMedCentralCrossRefPubMed Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6(1):78–95. 10.1007/s11306-009-0178-yPubMedCentralCrossRefPubMed
48.
Zurück zum Zitat Wei J, Xie G, Zhou Z, Shi P, Qiu Y, Zheng X, Chen T, Su M, Zhao A, Jia W: Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer 2011, 129(9):2207–17. 10.1002/ijc.25881CrossRefPubMed Wei J, Xie G, Zhou Z, Shi P, Qiu Y, Zheng X, Chen T, Su M, Zhao A, Jia W: Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer 2011, 129(9):2207–17. 10.1002/ijc.25881CrossRefPubMed
49.
Zurück zum Zitat Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, Gavish M, Nagler RM: Salivary analysis of oral cancer biomarkers. Br J Cancer 2009, 101(7):1194–8. 10.1038/sj.bjc.6605290PubMedCentralCrossRefPubMed Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, Gavish M, Nagler RM: Salivary analysis of oral cancer biomarkers. Br J Cancer 2009, 101(7):1194–8. 10.1038/sj.bjc.6605290PubMedCentralCrossRefPubMed
50.
Zurück zum Zitat Zhong L, Chen G, Xu Z, Zhang X, Ping F, Zhao S: Detection of telomerase activity in saliva from oral squamous cell carcinoma patients. Int J Oral and Maxillofac Surg 2005, 34: 366–370.CrossRef Zhong L, Chen G, Xu Z, Zhang X, Ping F, Zhao S: Detection of telomerase activity in saliva from oral squamous cell carcinoma patients. Int J Oral and Maxillofac Surg 2005, 34: 366–370.CrossRef
51.
Zurück zum Zitat El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, Clayman GL, Lippman S, Goepfert H: Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001, 3(4):164–70. 10.1016/S1525-1578(10)60668-XPubMedCentralCrossRefPubMed El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, Clayman GL, Lippman S, Goepfert H: Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001, 3(4):164–70. 10.1016/S1525-1578(10)60668-XPubMedCentralCrossRefPubMed
52.
Zurück zum Zitat Agha-Hosseini F, Mirzaii-Dizgah I, Farmanbar N, Abdollahi M: Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2012, 41(10):736–40. 10.1111/j.1600-0714.2012.01172.xCrossRefPubMed Agha-Hosseini F, Mirzaii-Dizgah I, Farmanbar N, Abdollahi M: Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2012, 41(10):736–40. 10.1111/j.1600-0714.2012.01172.xCrossRefPubMed
53.
Zurück zum Zitat Bernabe DG, Tamae AC, Miyahara GI, Sundefeld ML, Oliveira SP, Biasoli ER: Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. J Clin Pathol 2012, 65(10):934–9. 10.1136/jclinpath-2012-200695CrossRefPubMed Bernabe DG, Tamae AC, Miyahara GI, Sundefeld ML, Oliveira SP, Biasoli ER: Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. J Clin Pathol 2012, 65(10):934–9. 10.1136/jclinpath-2012-200695CrossRefPubMed
54.
Zurück zum Zitat He H, Chen G, Zhou L, Liu Y: A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland. J Cancer Res Clin Oncol 2009, 135(10):1315–21. 10.1007/s00432-009-0572-xCrossRefPubMed He H, Chen G, Zhou L, Liu Y: A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland. J Cancer Res Clin Oncol 2009, 135(10):1315–21. 10.1007/s00432-009-0572-xCrossRefPubMed
55.
Zurück zum Zitat Shpitzer T, Bahar G, Feinmesser R, Nagler RM: A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol 2007, 133(9):613–7. 10.1007/s00432-007-0207-zCrossRefPubMed Shpitzer T, Bahar G, Feinmesser R, Nagler RM: A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol 2007, 133(9):613–7. 10.1007/s00432-007-0207-zCrossRefPubMed
56.
Zurück zum Zitat Tang H, Wu Z, Zhang J, Su B: Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 2013, 7(3):761–6.PubMed Tang H, Wu Z, Zhang J, Su B: Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 2013, 7(3):761–6.PubMed
57.
Zurück zum Zitat Balan JJ, Rao RS, Premalatha BR, Patil S: Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. J Contemp Dent Pract 2012, 13(5):671–5.CrossRefPubMed Balan JJ, Rao RS, Premalatha BR, Patil S: Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. J Contemp Dent Pract 2012, 13(5):671–5.CrossRefPubMed
58.
Zurück zum Zitat Shetty SR, Chadha R, Babu S, Kumari S, Bhat S, Achalli S: Salivary lactate dehydrogenase levels in oral leukoplakia and oral squamous cell carcinoma: a biochemical and clinicopathological study. J Cancer Res Ther 2012, 8(Suppl 1):S123–5.PubMed Shetty SR, Chadha R, Babu S, Kumari S, Bhat S, Achalli S: Salivary lactate dehydrogenase levels in oral leukoplakia and oral squamous cell carcinoma: a biochemical and clinicopathological study. J Cancer Res Ther 2012, 8(Suppl 1):S123–5.PubMed
59.
Zurück zum Zitat Jessie K, Jayapalan JJ, Ong KC, Abdul Rahim ZH, Zain RM, Wong KT, Hashim OH: Aberrant proteins in the saliva of patients with oral squamous cell carcinoma. Electrophoresis 2013, 34(17):2495–502. 10.1002/elps.201300107CrossRefPubMed Jessie K, Jayapalan JJ, Ong KC, Abdul Rahim ZH, Zain RM, Wong KT, Hashim OH: Aberrant proteins in the saliva of patients with oral squamous cell carcinoma. Electrophoresis 2013, 34(17):2495–502. 10.1002/elps.201300107CrossRefPubMed
60.
Zurück zum Zitat Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, Tsai MH, Chen SY, Kao JY, Lin CW: Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta 2011, 412(15–16):1357–65.CrossRefPubMed Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, Tsai MH, Chen SY, Kao JY, Lin CW: Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta 2011, 412(15–16):1357–65.CrossRefPubMed
61.
Zurück zum Zitat Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, Chang S, Brait M, Jiang WW, Kim MM, Claybourne Q, Goldenberg D, Khan Z, Khan T, Westra WH, Sidransky D, Koch W, Califano JA: Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 2011, 17(14):4782–9. 10.1158/1078-0432.CCR-11-0324PubMedCentralCrossRefPubMed Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, Chang S, Brait M, Jiang WW, Kim MM, Claybourne Q, Goldenberg D, Khan Z, Khan T, Westra WH, Sidransky D, Koch W, Califano JA: Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 2011, 17(14):4782–9. 10.1158/1078-0432.CCR-11-0324PubMedCentralCrossRefPubMed
62.
Zurück zum Zitat Contucci AM, Inzitari R, Agostino S, Vitali A, Fiorita A, Cabras T, Scarano E, Messana I: Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report. Oral Dis 2005, 11(2):95–9. 10.1111/j.1601-0825.2004.01057.xCrossRefPubMed Contucci AM, Inzitari R, Agostino S, Vitali A, Fiorita A, Cabras T, Scarano E, Messana I: Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report. Oral Dis 2005, 11(2):95–9. 10.1111/j.1601-0825.2004.01057.xCrossRefPubMed
63.
Zurück zum Zitat Hoffmann RR, Yurgel LS, Campos MM: Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia. Regul Pept 2011, 166(1–3):55–8.CrossRefPubMed Hoffmann RR, Yurgel LS, Campos MM: Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia. Regul Pept 2011, 166(1–3):55–8.CrossRefPubMed
64.
Zurück zum Zitat Magnusson M, Pyykko I, van Setten G, Norlander T, Nastri A, Westermark A: Basic fibroblast growth factor (bFGF) in saliva and oral mucosa in patients with oral lichen planus: preliminary observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 98(3):324–6. 10.1016/j.tripleo.2004.02.056CrossRefPubMed Magnusson M, Pyykko I, van Setten G, Norlander T, Nastri A, Westermark A: Basic fibroblast growth factor (bFGF) in saliva and oral mucosa in patients with oral lichen planus: preliminary observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 98(3):324–6. 10.1016/j.tripleo.2004.02.056CrossRefPubMed
65.
Zurück zum Zitat Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, Holmstrup P, Mutlu S, Porter S, Wray D: Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 1998, 9(1):86–122. 10.1177/10454411980090010501CrossRefPubMed Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, Holmstrup P, Mutlu S, Porter S, Wray D: Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med 1998, 9(1):86–122. 10.1177/10454411980090010501CrossRefPubMed
66.
Zurück zum Zitat Neville BW, Day TA: Oral cancer and precancerous lesions. CA Cancer J Clin 2002, 52(4):195–215. 10.3322/canjclin.52.4.195CrossRefPubMed Neville BW, Day TA: Oral cancer and precancerous lesions. CA Cancer J Clin 2002, 52(4):195–215. 10.3322/canjclin.52.4.195CrossRefPubMed
67.
Zurück zum Zitat Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F: A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005, 114(3):278–83. 10.1016/j.clim.2004.12.003CrossRefPubMed Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F: A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005, 114(3):278–83. 10.1016/j.clim.2004.12.003CrossRefPubMed
68.
Zurück zum Zitat Teles RP, Likhari V, Socransky SS, Haffajee AD: Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res 2009, 44(3):411–7. 10.1111/j.1600-0765.2008.01119.xPubMedCentralCrossRefPubMed Teles RP, Likhari V, Socransky SS, Haffajee AD: Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res 2009, 44(3):411–7. 10.1111/j.1600-0765.2008.01119.xPubMedCentralCrossRefPubMed
69.
Zurück zum Zitat Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, Bai J, Gao F, Zhou M, Chen Q: NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008, 41(2):144–9. 10.1016/j.cyto.2007.11.004CrossRefPubMed Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, Bai J, Gao F, Zhou M, Chen Q: NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008, 41(2):144–9. 10.1016/j.cyto.2007.11.004CrossRefPubMed
70.
Zurück zum Zitat Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT: Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 2008, 14(8):705–12. 10.1111/j.1601-0825.2008.01488.xPubMedCentralCrossRefPubMed Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT: Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 2008, 14(8):705–12. 10.1111/j.1601-0825.2008.01488.xPubMedCentralCrossRefPubMed
71.
Zurück zum Zitat Sharma M, Bairy I, Pai K, Satyamoorthy K, Prasad S, Berkovitz B, Radhakrishnan R: Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis. Clin Oral Investig 2011, 15(5):705–14. 10.1007/s00784-010-0435-5CrossRefPubMed Sharma M, Bairy I, Pai K, Satyamoorthy K, Prasad S, Berkovitz B, Radhakrishnan R: Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis. Clin Oral Investig 2011, 15(5):705–14. 10.1007/s00784-010-0435-5CrossRefPubMed
72.
Zurück zum Zitat Ebersole JL, Schuster JL, Stevens J, Dawson D 3rd, Kryscio RJ, Lin Y, Thomas MV, Miller CS: Patterns of salivary analytes provide diagnostic capacity for distinguishing chronic adult periodontitis from health. J Clin Immunol 2013, 33(1):271–9. 10.1007/s10875-012-9771-3PubMedCentralCrossRefPubMed Ebersole JL, Schuster JL, Stevens J, Dawson D 3rd, Kryscio RJ, Lin Y, Thomas MV, Miller CS: Patterns of salivary analytes provide diagnostic capacity for distinguishing chronic adult periodontitis from health. J Clin Immunol 2013, 33(1):271–9. 10.1007/s10875-012-9771-3PubMedCentralCrossRefPubMed
73.
Zurück zum Zitat Thomas MV, Branscum A, Miller CS, Ebersole J, Al-Sabbagh M, Schuster JL: Within-subject variability in repeated measures of salivary analytes in healthy adults. J Periodontol 2009, 80(7):1146–53. 10.1902/jop.2009.080654PubMedCentralCrossRefPubMed Thomas MV, Branscum A, Miller CS, Ebersole J, Al-Sabbagh M, Schuster JL: Within-subject variability in repeated measures of salivary analytes in healthy adults. J Periodontol 2009, 80(7):1146–53. 10.1902/jop.2009.080654PubMedCentralCrossRefPubMed
74.
Zurück zum Zitat Kim JK, Zhou H, Nabili V, Wang MB, Abemayor E, Wong DT: Utility of multiple sampling in reducing variation of salivary interleukin-8 and interleukin-1beta mRNA levels in healthy adults. Head Neck 2012, 35(7):968–73.CrossRefPubMed Kim JK, Zhou H, Nabili V, Wang MB, Abemayor E, Wong DT: Utility of multiple sampling in reducing variation of salivary interleukin-8 and interleukin-1beta mRNA levels in healthy adults. Head Neck 2012, 35(7):968–73.CrossRefPubMed
75.
Zurück zum Zitat Jehmlich N, Dinh KH, Gesell-Salazar M, Hammer E, Steil L, Dhople VM, Schurmann C, Holtfreter B, Kocher T, Volker U: Quantitative analysis of the intra- and inter-subject variability of the whole salivary proteome. J Periodontal Res 2012, 48(3):392–403.CrossRefPubMed Jehmlich N, Dinh KH, Gesell-Salazar M, Hammer E, Steil L, Dhople VM, Schurmann C, Holtfreter B, Kocher T, Volker U: Quantitative analysis of the intra- and inter-subject variability of the whole salivary proteome. J Periodontal Res 2012, 48(3):392–403.CrossRefPubMed
76.
Zurück zum Zitat Fraser CG: Inherent biological variation and reference values. Clin Chem Lab Med 2004, 42(7):758–64.CrossRefPubMed Fraser CG: Inherent biological variation and reference values. Clin Chem Lab Med 2004, 42(7):758–64.CrossRefPubMed
77.
Zurück zum Zitat Denver R, Tzanidis A, Martin P, Krum H: Salivary endothelin concentrations in the assessment of chronic heart failure. Lancet 2000, 355(9202):468–9. 10.1016/S0140-6736(00)82019-XCrossRefPubMed Denver R, Tzanidis A, Martin P, Krum H: Salivary endothelin concentrations in the assessment of chronic heart failure. Lancet 2000, 355(9202):468–9. 10.1016/S0140-6736(00)82019-XCrossRefPubMed
78.
Zurück zum Zitat Lam HC, Lo GH, Lee JK, Lu CC, Chu CH, Sun CC, Chuang MJ, Wang MC: Salivary immunoreactive endothelin in patients with upper gastrointestinal diseases. J Cardiovasc Pharmacol 2004, 44(Suppl 1):S413–7.CrossRefPubMed Lam HC, Lo GH, Lee JK, Lu CC, Chu CH, Sun CC, Chuang MJ, Wang MC: Salivary immunoreactive endothelin in patients with upper gastrointestinal diseases. J Cardiovasc Pharmacol 2004, 44(Suppl 1):S413–7.CrossRefPubMed
79.
Zurück zum Zitat Dodds MW, Johnson DA, Yeh CK: Health benefits of saliva: a review. J Dent 2005, 33(3):223–33. 10.1016/j.jdent.2004.10.009CrossRefPubMed Dodds MW, Johnson DA, Yeh CK: Health benefits of saliva: a review. J Dent 2005, 33(3):223–33. 10.1016/j.jdent.2004.10.009CrossRefPubMed
80.
Zurück zum Zitat Denny PC, Denny PA, Klauser DK, Hong SH, Navazesh M, Tabak LA: Age-related changes in mucins from human whole saliva. J Dent Res 1991, 70(10):1320–7. 10.1177/00220345910700100201CrossRefPubMed Denny PC, Denny PA, Klauser DK, Hong SH, Navazesh M, Tabak LA: Age-related changes in mucins from human whole saliva. J Dent Res 1991, 70(10):1320–7. 10.1177/00220345910700100201CrossRefPubMed
81.
Zurück zum Zitat Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R: NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009, 13(4):631–43. 10.1111/j.1582-4934.2009.00632.xPubMedCentralCrossRefPubMed Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R: NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009, 13(4):631–43. 10.1111/j.1582-4934.2009.00632.xPubMedCentralCrossRefPubMed
82.
Zurück zum Zitat Hom D: Growth factors in wound healing. Otolaryngol Clin North Am 1995, 28(5):933–53.PubMed Hom D: Growth factors in wound healing. Otolaryngol Clin North Am 1995, 28(5):933–53.PubMed
83.
Zurück zum Zitat Canakci C, Cicek Y, Yildirim A, Sezer U, Canakci V: Increased levels of 8-hydroxydeoxyguanosine and malondialdehyde and its relationship with antioxidant enzymes in saliva of periodontitis patients. European Journal of Dentistry 2009, 3: 100–106.PubMedCentralPubMed Canakci C, Cicek Y, Yildirim A, Sezer U, Canakci V: Increased levels of 8-hydroxydeoxyguanosine and malondialdehyde and its relationship with antioxidant enzymes in saliva of periodontitis patients. European Journal of Dentistry 2009, 3: 100–106.PubMedCentralPubMed
84.
Zurück zum Zitat Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M: Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol 2009, 36(11):922–7. 10.1111/j.1600-051X.2009.01480.xCrossRefPubMed Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M: Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol 2009, 36(11):922–7. 10.1111/j.1600-051X.2009.01480.xCrossRefPubMed
85.
Zurück zum Zitat Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, Karlan B, Wong DT: Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 2010, 5(12):e15573. 10.1371/journal.pone.0015573PubMedCentralCrossRefPubMed Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, Karlan B, Wong DT: Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 2010, 5(12):e15573. 10.1371/journal.pone.0015573PubMedCentralCrossRefPubMed
86.
Zurück zum Zitat Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT: Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 2012, 11(2):M111 012112. 10.1074/mcp.M111.012112PubMedCentralCrossRefPubMed Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT: Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 2012, 11(2):M111 012112. 10.1074/mcp.M111.012112PubMedCentralCrossRefPubMed
87.
Zurück zum Zitat Bigler LR, Streckfus CF, Dubinsky WP: Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009, 29(1):71–85. 10.1016/j.cll.2009.01.004CrossRefPubMed Bigler LR, Streckfus CF, Dubinsky WP: Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009, 29(1):71–85. 10.1016/j.cll.2009.01.004CrossRefPubMed
88.
Zurück zum Zitat Streckfus C, Bigler L, Tucci M, Thigpen JT: A preliminary study of CA15–3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 2000, 18(2):101–9. 10.3109/07357900009038240CrossRefPubMed Streckfus C, Bigler L, Tucci M, Thigpen JT: A preliminary study of CA15–3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 2000, 18(2):101–9. 10.3109/07357900009038240CrossRefPubMed
89.
Zurück zum Zitat Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT: The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000, 6(6):2363–70.PubMed Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT: The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000, 6(6):2363–70.PubMed
90.
Zurück zum Zitat Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH, Wong DT: Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci 2012, 69(19):3341–50. 10.1007/s00018-012-1027-0PubMedCentralCrossRefPubMed Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH, Wong DT: Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci 2012, 69(19):3341–50. 10.1007/s00018-012-1027-0PubMedCentralCrossRefPubMed
91.
Zurück zum Zitat Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi M: Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009, 10(6):E001–8.PubMed Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi M: Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009, 10(6):E001–8.PubMed
92.
Zurück zum Zitat Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A: Correlation of serum and salivary CA15–3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal 2009, 14(10):e521–4.CrossRefPubMed Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A: Correlation of serum and salivary CA15–3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal 2009, 14(10):e521–4.CrossRefPubMed
Metadaten
Titel
A review of research on salivary biomarkers for oral cancer detection
verfasst von
Yi-Shing Lisa Cheng
Terry Rees
John Wright
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical and Translational Medicine / Ausgabe 1/2014
Elektronische ISSN: 2001-1326
DOI
https://doi.org/10.1186/2001-1326-3-3

Weitere Artikel der Ausgabe 1/2014

Clinical and Translational Medicine 1/2014 Zur Ausgabe